THE Therapeutic Goods
Administration has approved
Tarceva (erlotinib) for first-line
maintenance treatment in nonsmall
cell lung cancer.
The approval is for patients who
have not progressed on first-line
chemotherapy.
Tarceva is an oral epidermal
growth factor receptor (EGFR)
tyrosine-kinase inhibitor.
It blocks tumour cell growth by
inhibiting the tyrosine kinase
activity of the HER1 signalling
pathway inside the cells.
Tarceva is also approved for the
treatment of lung cancer patients
who have failed chemotherapy, as
well as for locally advanced,
unresectable or metastatic
pancreatic cancer.The above article was sent to subscribers in Pharmacy Daily's issue from 17 Nov 10 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 17 Nov 10
THE role and significance of community pharmacy in regional areas was a key focus of discussion for the Nationals leader David Littleproud during last week’s visit to Orana Mall Pharmacy as part of a regional tour.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.